Analysts expect Forty Seven Inc (NASDAQ:FTSV) to post earnings of ($0.56) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Forty Seven’s earnings. The firm is scheduled to issue its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Forty Seven will report full year earnings of ($2.91) per share for the current financial year, with EPS estimates ranging from ($3.51) to ($2.30). For the next financial year, analysts anticipate that the company will post earnings of ($2.73) per share, with EPS estimates ranging from ($3.05) to ($2.41). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Forty Seven.
Forty Seven (NASDAQ:FTSV) last posted its quarterly earnings data on Monday, August 13th. The company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($1.84).
Shares of Forty Seven stock traded up $0.15 on Thursday, hitting $15.11. The company had a trading volume of 201,159 shares, compared to its average volume of 101,404. Forty Seven has a 52 week low of $14.09 and a 52 week high of $16.86.
In other Forty Seven news, major shareholder Lifesciences Iii L.P. Clarus bought 200,000 shares of Forty Seven stock in a transaction that occurred on Monday, July 2nd. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $3,200,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stefan A. Dyckerhoff bought 136,650 shares of Forty Seven stock in a transaction that occurred on Monday, July 2nd. The shares were acquired at an average price of $16.00 per share, with a total value of $2,186,400.00. The disclosure for this purchase can be found here. Insiders have purchased 805,400 shares of company stock valued at $12,886,400 over the last 90 days.
Large investors have recently modified their holdings of the stock. Dean Capital Investments Management LLC bought a new stake in Forty Seven during the second quarter worth approximately $638,000. Citadel Advisors LLC bought a new stake in Forty Seven during the second quarter worth approximately $3,751,000. Laurion Capital Management LP bought a new stake in Forty Seven during the second quarter worth approximately $2,000,000. Millennium Management LLC purchased a new stake in shares of Forty Seven in the 2nd quarter valued at approximately $1,940,000. Finally, Acuta Capital Partners LLC purchased a new stake in shares of Forty Seven in the 2nd quarter valued at approximately $1,168,000. Hedge funds and other institutional investors own 1.26% of the company’s stock.
About Forty Seven
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.
Featured Article: Investing in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.